-
公开(公告)号：US20160166544A1
公开(公告)日：2016-06-16
申请号：US14906085
申请日：2014-08-25
申请人： Vincent Brett Cooper , Kathryn Alanna Bradley , Samuel Robert PYGALL , Rajan GUPTA , Madison Paige Stanford , Lin XIE , Merck Sharp & Dohme Corp. , Merck Sharp & Dohme Limited
发明人： Vincent Brett Cooper , Kathryn Alanna Bradley , Samuel Robert Pygall , Rajan Gupta , Madison Paige Stanford , Lin Xie
CPC分类号： A61K31/4162 , A61K9/0053 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K9/2866 , A61K47/12 , A61K47/26 , A61K47/38
摘要： The present invention is directed to stable, oral pharmaceutical formulations of dipeptidyl peptidase-4 inhibitors, such as omarigliptin. Such pharmaceutical formulations comprise omarigliptin; and neutral excipients, wherein the neutral excipient is present in the amount of at least 75% by weight of the pharmaceutical formulation and comprises at least one non-reducible sugar diluent or a mixture of non-reducible sugar diluents.
摘要翻译： 本发明涉及二肽基肽酶-4抑制剂的稳定的口服药物制剂，例如奥马立普。 这种药物制剂包含奥马立普; 和中性赋形剂，其中所述中性赋形剂以所述药物制剂的至少75重量％的量存在，并且包含至少一种不可还原糖稀释剂或不可还原糖稀释剂的混合物。
-
公开(公告)号：US09937153B2
公开(公告)日：2018-04-10
申请号：US14906085
申请日：2014-08-25
发明人： Vincent Brett Cooper , Kathryn Alanna Bradley , Samuel Robert Pygall , Rajan Gupta , Madison Paige Stanford , Lin Xie
CPC分类号： A61K31/4162 , A61K9/0053 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K9/2866 , A61K47/12 , A61K47/26 , A61K47/38
摘要： The present invention is directed to stable, oral pharmaceutical formulations of dipeptidyl peptidase-4 inhibitors, such as omarigliptin. Such pharmaceutical formulations comprise omarigliptin; and neutral excipients, wherein the neutral excipient is present in the amount of at least 75% by weight of the pharmaceutical formulation and comprises at least one non-reducible sugar diluent or a mixture of non-reducible sugar diluents.
-
搜索结果
2 条记录 (耗时 0.024 秒)
